These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32336278)

  • 1. Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort.
    Khoury G; Morel J; Combe B; Lukas C
    Arthritis Res Ther; 2020 Apr; 22(1):94. PubMed ID: 32336278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.
    Lian F; Zhou J; Wei C; Wang Y; Xu H; Liang L; Yang X
    Clin Rheumatol; 2015 Nov; 34(11):1913-20. PubMed ID: 26070537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
    Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
    Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
    Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
    Calvo-Río V; Blanco R; Santos-Gómez M; Rubio-Romero E; Cordero-Coma M; Gallego-Flores A; Veroz R; Torre I; Hernández FF; Atanes A; Loricera J; González-Vela MC; Palmou N; Hernández JL; González-Gay MA
    Semin Arthritis Rheum; 2016 Aug; 46(1):95-101. PubMed ID: 27060872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uveitis in Spondyloarthritis: An Overview.
    Cantini F; Nannini C; Cassarà E; Kaloudi O; Niccoli L
    J Rheumatol Suppl; 2015 Nov; 93():27-9. PubMed ID: 26523051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis.
    Bechman K; Yang Z; Adas M; Nagra D; S Uğuzlar A; Russell MD; Wilson N; Steer S; Norton S; Galloway J
    Arthritis Rheumatol; 2024 May; 76(5):704-714. PubMed ID: 38116697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials.
    Roche D; Badard M; Boyer L; Lafforgue P; Pham T
    Arthritis Res Ther; 2021 Jul; 23(1):192. PubMed ID: 34271991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.
    Hebeisen M; Scherer A; Micheroli R; Nissen MJ; Tamborrini G; Möller B; Zufferey P; Exer P; Ciurea A
    PLoS One; 2019; 14(5):e0216746. PubMed ID: 31145730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into uveitis in association with spondyloarthritis from a large patient survey.
    Keck KM; Choi D; Savage LM; Rosenbaum JT
    J Clin Rheumatol; 2014 Apr; 20(3):141-5. PubMed ID: 24662555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis.
    Terlemez R; Akgün K; Palamar D; Boz S; Sarı H
    Clin Rheumatol; 2017 May; 36(5):1071-1076. PubMed ID: 28357602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
    Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
    Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients.
    Frantz C; Portier A; Etcheto A; Monnet D; Brezin A; Roure F; Elhai M; Burki V; Fabreguet I; Koumakis E; Payet J; Gossec L; Dougados M; Molto A
    Clin Exp Rheumatol; 2019; 37(1):26-31. PubMed ID: 30620268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
    Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.
    Gratacós J; Pontes C; Juanola X; Sanz J; Torres F; Avendaño C; Vallano A; Calvo G; de Miguel E; Sanmartí R;
    Arthritis Res Ther; 2019 Jan; 21(1):11. PubMed ID: 30621746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
    Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
    Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.